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Burkholderia mallei and B. pseudomallei are important human pathogens and cause the diseases glanders and
melioidosis, respectively. Both organisms are highly infectious when inhaled and are inherently resistant to
many antimicrobials, thus making it difficult to treat pneumonic Burkholderia infections. We investigated
whether it was possible to achieve rapid protection against inhaled Burkholderia infection by using inhaled
immunotherapy. For this purpose, cationic liposome DNA complexes (CLDC), which are potent activators of
innate immunity, were used to elicit the activation of pulmonary innate immune responses. We found that
mucosal CLDC administration before or shortly after bacterial challenge could generate complete or nearly
complete protection from inhalational challenge with 100% lethal doses of B. mallei and B. pseudomallei.
Protection was found to be dependent on the CLDC-mediated induction of gamma interferon responses in lung
tissues and was partially dependent on the activation of NK cells. However, CLDC-mediated protection was not
dependent on the induction of inducible nitric oxide synthase, as assessed by depletion studies. We concluded
that the potent local activation of innate immune responses in the lung could be used to elicit rapid and
nonspecific protection from aerosol exposure to both B. mallei and B. pseudomallei.
Pathogenic Burkholderia species, including B. mallei and B.
pseudomallei, are gram-negative facultative intracellular bacte-
ria. Burkholderia pseudomallei is a soil bacterium that causes a
disease known as melioidosis, while B. mallei is an obligate
mammalian pathogen that causes glanders (26, 37). The pri-
mary host for B. mallei is equines, though the organism also
can infect other mammals, including humans (21, 22). Without
antimicrobial therapy, infection with B. mallei is nearly 100%
fatal (37). Both B. mallei and B. pseudomallei are classified as
category B select agents by the Centers for Disease Control
and Prevention due to their high potential for use as bioweap-
ons and their high resistance to antibiotics (1, 28, 33, 39).
Currently, prolonged (up to 6 months) antimicrobial therapy of
Burkholderia infection is required (31, 40). Currently there is
no vaccine available for preventing infection with Burkholderia
organisms.
Proinflammatory cytokines are critical for generating pro-
tective immunity to acute Burkholderia infection. For example,
mice unable to produce interleukin-12 (IL-12) are highly sus-
ceptible to infection with B. mallei, and treatment with recom-
binant IL-12 provides partial protection against infection. (2,
29). Tumor necrosis factor  (TNF-) also plays an important
protective role in B. pseudomallei infection, as the antibody
neutralization of TNF- increases susceptibility to infection,
and TNF-/ and TNF--receptor/ (TNF--R/) mice
are highly susceptible to lethal infection (4, 30). Gamma inter-
feron (IFN-) also is critical in generating protective immunity
to Burkholderia infection (29, 30). Indeed, even very low con-
centrations of IFN- are sufficient to generate protection
against B. pseudomallei infection (14).
Given the inherent antimicrobial resistance of Burkholderia
and the lack of effective vaccines, there is a need for alternative
approaches to rapidly protect from aerosol infection. The non-
specific activation of innate immunity by the administration of
immunotherapeutics represents one such approach. For exam-
ple, it was shown previously that the systemic (intraperitoneal
[i.p.]) administration of CpG oligonucleotides prior to in-
fection provided protection against low-dose aerosol B. mal-
lei challenge (38). A similar CpG oligonucleotide treatment
approach also was shown to be effective against systemic
challenge with B. pseudomallei (41). However, an inhaled
immunotherapeutic could be more rapidly administered and
generate protective immunity more rapidly than a parenter-
ally administered agent. Therefore, we evaluated the poten-
tial effectiveness of a mucosally administered immunother-
apeutic for protection from inhaled Burkholderia infection.
The studies described here used cationic liposome-DNA
complexes (CLDC) as immunotherapeutics, as our previous
investigations have shown CLDC to be potent inducers of
innate immunity (11).
We investigated the effects of the timing of mucosal CLDC
administration on the induction of protective immunity and
whether CLDC immunotherapy could protect against both B.
mallei and B. pseudomallei infection. These studies also used a
rigorous high-dose inhalational Burkholderia challenge model
and investigated immunological mechanisms of protection. We
report here that the intranasal (i.n.) administration of a
liposome-based immunotherapeutic was capable of eliciting
significant protection from pneumonic Burkholderia infec-
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tion. These results suggest that this approach is an effective
strategy for generating rapid and nonspecific protection
from the inhalation of acutely pathogenic bacteria.
MATERIALS AND METHODS
Mice. Female BALB/c mice and IFN-/ mice on the BALB/c background
were used in this study (Jackson Laboratories, Bar Harbor, ME). All mice were
6 to 8 weeks of age at the time of infection and were housed under pathogen-free
conditions. We determined that BALB/c mice were more susceptible to B. mallei
infection by the i.n. route than C57BL/6 mice, which is consistent with results
obtained by other investigators in prior studies (12, 37).
Preparation and administration of CLDC. Sterile complexes of cationic lipo-
somes were prepared using equimolar amounts of DOTIM [octadecanoyloxy
(ethyl-2-heptadecenyl-3-hydroxyethyl) imidazolinium chloride] and cholesterol,
which were prepared as described previously, except that the liposomes were
extruded through a final filter diameter of 200 nm rather than 100 nm (32).
Liposome-DNA complexes were formed just prior to injection by gently mixing
cationic liposomes with plasmid DNA in 5% dextrose in water at room temper-
ature. The final plasmid DNA concentration in the complexes was 200 g DNA
per ml. Plasmid DNA was isolated from Escherichia coli DH5 using the Qiagen
Endo-free Giga kit according to the manufacturer’s instructions (Qiagen, Va-
lencia, CA). The plasmid used for these experiments was a eukaryotic expression
plasmid that contained no transgene insert, as described previously (11). CLDC
were administered to mice i.n. in a 20-l volume (10 l per nostril).
Preparation of Burkholderia mallei and B. pseudomallei stocks and animal
infections. Burkholderia mallei (strain ATCC 23344) and Burkholderia pseudoma-
llei (strain 1026b) both were kindly provided by Herbert Schweizer, Colorado
State University. All animal procedures were approved by the Animal Care and
Use Committee at Colorado State University. All procedures involving Burk-
holderia were performed in a biosafety level 3 facility, in accordance with select
agent regulations and with Institutional Biosafety Committee oversight at Col-
orado State University.
For B. mallei studies, the ATCC 23344 B. mallei strain first was serially
passaged three times by animal infection in mice. The use of animal passage has
been reported previously to increase the virulence of B. mallei, and we observed
the same phenomenon in our studies (27, 37). In addition, prior to each in vivo
or in vitro infection with B. mallei, fresh broth cultures were grown in brucella
broth supplemented with 4% glycerol (BB4G) (Remel, Lenexa, KS). Bacteria
were harvested during the log phase of growth, titers were determined based on
optical density values, and bacterial dilutions were prepared in sterile phosphate-
buffered saline (PBS). Bacterial titers (in CFU) of each inocula were determined
by plating serial dilutions of the inocula on BB4G agar plates (Remel).
Prior to infection, mice were anesthetized by the i.p. injection of ketamine
(Fort Dodge Animal Health, Overland Park, KS) and xylazine (Ben Venue
Laboratories, Bedford, OH) solution prepared in sterile water. Mice were in-
fected with B. mallei i.n. using a total volume of 20 l of inoculum (10 l per
nostril). Animal challenge studies were conducted to determine the 50% lethal
dose (LD50) and LD100 of B. mallei in BALB/c mice. The LD50 of B. mallei in
BALB/c mice by the i.n. route was determined by the Reed-Meunch method to
be 820 CFU, and the experimental LD100 was 4.2  103 CFU. For in vitro
experiments with B. mallei, frozen stocks of known titers of the animal-passaged
B. mallei were diluted in cell culture media, added to cells, and incubated at 37°C
for the indicated amount of time and at the indicated MOI.
Frozen stocks of B. pseudomallei of known titers were prepared from cultures
grown in Luria-Bertani (LB) broth (BD Biosciences, San Jose, CA) by freezing
the cultures in LB medium containing 20% glycerol. Inocula for in vivo infection
with B. pseudomallei were prepared by thawing and diluting frozen stocks in
sterile PBS. The LD50 of B. pseudomallei in BALB/c mice by the i.n. route was
determined by the Reed-Meunch method to be 900 CFU, and the experimental
LD100 was 4.5  103 CFU.
Determination of bacterial burden in tissues. To determine bacterial burdens
in lung, liver, and spleen tissues of infected mice, the mice were humanely
euthanized, and organs from each mouse were harvested and placed in 5 ml
sterile PBS. Organs were homogenized using a Stomacher 80 Biomaster (Seward,
Bohemia, NY). Serial 10-fold dilutions of supernatants then were prepared in
sterile saline and plated on BB4G agar plates (Remel). Agar plates were incu-
bated at 37°C for 48 h, and colonies were counted. The limit of detection for the
determination of the bacterial burden was either 50 or 100 CFU/organ, depend-
ing on the experiment.
Histological analyses. Lung, liver, and spleen tissues were harvested and
placed in 10% formalin for 24 h. In the case of lung tissues, the lungs were
inflated with formalin via tracheal injection prior to being removed and then
were placed in formalin solution for 24 h. After 24 h, organs were transferred
into 70% ethanol for another 7 days. Tissues then were sectioned and stained
with hematoxylin and eosin. Organ pathology was assessed by an experienced
veterinary pathologist (H. Bielefeldt-Ohmann).
Cytokine quantitation. To assess the effects of immunotherapy on cytokine
production in the lungs, CLDC (or diluent) was administered i.n. to mice (n 
4 per group), which were euthanized 6 or 24 h later. Lungs were harvested and
homogenized using a Stomacher 80 Biomaster (Seward) in 4 ml sterile saline.
The lung homogenate was clarified by centrifugation, and the supernatants were
frozen at 80°C prior to cytokine analysis. Concentrations of IL-12p40 and
IFN- were measured by commercial enzyme-linked immunosorbent assays
(ELISAs) according to the manufacturer’s instructions (R&D Systems, Minne-
apolis, MN).
In vitro infection of macrophages with B. mallei. The mouse alveolar macro-
phage cell line (AMJ2; American Type Tissue Collection, Manassas, VA) was
used to investigate the ability of CLDC supernatants to enhance bactericidal
activity in vitro. Cells were cultured in 24-well plates in complete medium
without antibiotics. Cells were cultured in complete medium that consisted of
minimal essential medium (Invitrogen, Carlsbad, CA) containing 10% fetal bo-
vine serum (Gemini Bio-Products, West Sacramento, CA), 2 mM L-glutamine
(Invitrogen), 1 nonessential amino acids (Invitrogen), and 0.075% sodium
bicarbonate (EMD Science, Gibbstown, NJ). Adherent cells were infected with
B. mallei at a multiplicity of infection (MOI) of 2 for 1 h in 250 l medium at
37°C and 5% CO2. Extracellular bacteria were removed by washing the cells
three times with PBS, followed by treatment with medium plus 350 g/ml kana-
mycin (Sigma-Aldrich) for 1 h. After incubation with kanamycin for 1 h, the cells
were washed and then cultured in complete medium with 10 g/ml kanamycin
for an additional 24 h. To quantitate intracellular bacterial numbers, the cells
were washed three times with PBS and then lysed with sterile double-distilled
water containing 0.01% Triton X-100. Serial dilutions of lysate were plated on
BB4G agar plates, and plates were incubated at 37°C for 48 h, at which time
colonies were counted.
Cytokine inhibition of macrophage infection with B. mallei. The ability of
cytokines elicited by CLDC immunotherapy to inhibit the intracellular replica-
tion of B. mallei in infected macrophages was assessed using AMJ2 alveolar
macrophages. AMJ2 cells (1  105 per well in triplicate wells of 24-well plates)
were pretreated for 24 h before infection with diluted (1:10 or 1:100) superna-
tants from spleen cells of mice treated in vivo with CLDC or with supernatants
from control spleen cells. Briefly, supernatants were generated as described
previously by using overnight cultures of spleen cells prepared from mice injected
intravenously (i.v.) with 200 l CLDC 3 h prior to sacrifice (11). It was deter-
mined by ELISA that the supernatants from spleen cells of CLDC-injected mice
contained 3 ng/ml IFN- and 140 pg/ml TNF- (data not shown).
Neutralizing antibodies were used to identify key cytokines that may have been
responsible for generating antibacterial activity in supernatants from spleen cells.
Thus, supernatants were treated with 10 g/ml anti-IFN- antibody (clone
R4.6A2) (eBioscience, San Diego, CA), 10 g/ml of anti-TNF- antibody (clone
TN3-19.12) (eBioscience), or a mixture of equal concentrations of both antibod-
ies. Controls included incubating the supernatants with equivalent amounts of
irrelevant isotype-matched antibodies (clones eBRG1 and eBio299Arm; eBio-
sciences) at 37°C for 30 min prior to the addition of supernatants to cells. Cells
were incubated with supernatants for 24 h and then infected with B. mallei, and
intracellular bacterial concentrations were determined as noted above. The ef-
fects of individual cytokines on inhibiting the B. mallei infection of AMJ2 cells
also were evaluated. AMJ2 cells were incubated with recombinant murine IFN-
(10 ng/ml; Preprotec, Rocky Hill, NJ) or murine TNF- (10 ng/ml; Preprotec) for
24 h prior to B. mallei infection. Twenty-four hours after infection, intracellular
concentrations of bacteria were determined as indicated above.
NK cell depletion. NK cells were depleted systemically in mice (n  5 per
group) by the injection of anti-asialo GM1 antibody (Wako Chemicals, Rich-
mond, VA), as described previously (9, 11, 13). Briefly, mice were injected i.p.
with 50 g of anti-asialo GM1 antibody 24 h prior to CLDC treatment. This
treatment was found to decrease the number of splenic and lung NK cells by
more than 75% (data not shown). The mice then were infected i.n. with B. mallei
24 h after that (48 h after the injection of asialo-GM1 antibody). Controls
included mice injected i.p. with an equivalent amount of rabbit immunoglobulin
G antibody (Jackson Immunoresearch, West Grove, PA).
Inhibition of nitric oxide production in vivo. Inducible nitric oxide synthase
(iNOS) activity was inhibited by the treatment of mice with aminoguanidine
(AG) (Sigma-Aldrich). Mice were injected i.p twice daily with 0.2 ml of a
50-mg/ml solution of AG prepared in PBS, starting 5 days prior to infection and
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continuing until 7 days post infection, using a previously described protocol (5,
7). Control mice were injected with an equal volume of sterile PBS.
Statistical analysis. Statistical analysis was performed using Prism 5.0 software
(GraphPad, La Jolla, CA). For the comparison of two groups, two-tailed t tests
were performed. For the comparison of more than two groups, one-way analysis
of variance (ANOVA) was done, followed by Tukey’s multiple means compar-
ison test. Survival times were compared using Kaplan-Meier curves and the
log-rank test. Data were considered statistically significant for P  0.05.
RESULTS
Mucosal administration of CLCD immunotherapy protects
mice from acute B. mallei pneumonic infection. Previous stud-
iesdemonstratedthatsystemic immunotherapyusingCpGoligo-
nucleotides could provide protection from chronic infection
following low-dose B. mallei pneumonia (38). However, we
wished to determine whether mucosal immunotherapy with a
liposome-based immunotherapeutic was effective in an acutely
lethal B. mallei pneumonia model. Therefore, we conducted
protection studies in mice challenged with a high dose (10
LD50) of B. mallei by the i.n. route.
In the first studies, we assessed the effects of the timing of
CLDC administration on the induction of protective immunity.
BALB/c mice (n  5 per group) were administered 20 l of
CLDC by the i.n. route, either 24 h prior to infection, concur-
rently with infection, or 24 h after infection. Mice then were
infected i.n. with 10 LD50 (approximately 1 10
4 CFU) of B.
mallei and monitored for effects on survival. We observed that
the administration of CLDC 24 h prior to infection generated
complete protection from lethal B. mallei infection (Fig. 1).
Concurrent i.n. administration of CLDC immunotherapy pro-
vided partial protection from lethal infection, whereas treat-
ment 24 h after infection did not generate significant protec-
tion (Fig. 1). In addition, the administration of CLDC 6 h after
infection also failed to elicit significant protection (data not
shown). We also noted that protection elicited by mucosal
CLDC immunotherapy prevented lethal acute infection but
failed to completely protect from chronic infection, as approx-
imately 50% of treated mice developed chronic infection by
day 60 after challenge (data not shown). Thus, pretreatment by
the i.n. administration of liposome-based immunotherapy was
sufficient to generate significant protection from high-dose in-
halational challenge with B. mallei.
Experiments then were conducted to assess the dose respon-
siveness of CLDC protection from B. mallei challenge by using
the 24 h of pretreatment model. Mice (n  5 per group) were
pretreated with the standard concentration of CLDC or with
CLDC diluted 1:2 or 1:20 in diluent (Fig. 1). We found that the
administration of CLDC diluted 1:2 still provided significant
(P  0.01) protection, whereas CLDC diluted 1:20 failed to
elicit protection.
We next assessed the ability of CLDC immunotherapy to
protect from a higher B. mallei challenge dose. Mice were
subjected to challenge with 50 LD50 (5  10
4 CFU), and the
effects on survival time were assessed. We found that CLDC
immunotherapy still provided significant protection in this
higher-dose challenge model. Though 80% of the mice suc-
cumbed to this high-dose challenge, the median survival time
for CLDC-treated mice was 4 days, whereas it was 2 days for
untreated mice (P 0.003) (data not shown). We also assessed
whether increasing the CLDC dose increased protection. In-
creasing the dose of CLDC administered by doubling the con-
centration of liposomes and plasmid DNA (and still adminis-
tering the same i.n. volume of CLDC) did not, however,
increase survival significantly over that elicited by the admin-
istration of the standard amount of CLDC (data not shown).
Burkholderia mallei and B. pseudomallei are related patho-
gens, but they also possess some key differences with respect to
genomic complexity and the numbers of potential virulence
factors (17, 25). Therefore, we conducted challenge studies
with B. pseudomallei to determine whether CLDC immuno-
therapy also was capable of eliciting protective immunity
against pneumonic infection with this organism. BALB/c mice
(n  5 per group) were treated with CLDC i.n. 24 h prior to
infection and then were subject to i.n. infection with 10 LD50
(1  104 CFU) of B. pseudomallei, and the effects on survival
times were assessed (Fig. 1). We found that CLDC immuno-
therapy was effective in completely protecting mice from lethal
pneumonic infection with B. pseudomallei. Thus, CLDC immu-
notherapy was capable of eliciting broadly protective immunity
against two species of Burkholderia.
Reduced bacterial burden and organ pathology in mice
treated with CLDC immunotherapy. The preceding studies
demonstrated that CLDC immunotherapy could protect
against lethal respiratory Burkholderia infection in a dose-de-
pendent fashion. Therefore, studies were conducted next to
elucidate the mechanisms of protection. First, the effects of
CLDC treatment on bacterial burdens in the lungs, spleen, and
liver were assessed. BALB/c mice (n 5 per group) were sham
treated or were treated with CLDC i.n. 24 h prior to infection
and then were subjected to infection with approximately 1 
104 CFU B. mallei i.n. The mice were euthanized 3 days after
infection and bacterial were burdens determined, as described
in Materials and Methods. We found that there were signifi-
cant (P  0.0001) reductions in the bacterial burdens in lung,
liver, and spleen in CLDC-treated mice compared to that in
untreated mice (Fig. 2).
CLDC immunotherapy did not, however, generate complete
sterilizing immunity. For example, nearly all CLDC-treated
mice, though they survived acute infection, eventually devel-
oped chronic disseminated B. mallei infection in the liver and
spleen. Bacterial burdens in the lung remained below the limit
of detection (50 CFU) on day 21, 30, 45, or 60 after infection.
However, increasing bacterial burdens were noted in the liver
and especially the spleen at later time points following CLDC
treatment and B. mallei challenge (data not shown).
Pretreatment with CLDC immunotherapy also substantially
reduced acute organ pathology in B. mallei-infected mice. In
untreated mice (n  4 per group) euthanized 3 days after B.
mallei challenge, there was marked neutrophil infiltration in
the lungs, along with hemorrhage from pulmonary vessels, the
necrosis of respiratory epithelium, and the apoptosis of leuko-
cytes and lung parenchyma (Fig. 3). In contrast, in CLDC-
treated mice the lung neutrophil infiltrate was reduced and
hemorrhage was not observed in pulmonary vessels.
In untreated B. mallei-infected mice, hepatic lesions con-
sisted of infiltrates of neutrophils and monocytes. In the livers
of untreated mice there were large areas of necrosis, and in
some mice hepatic lesions coalesced, whereas hepatic lesions
in CLDC treated mice showed no evidence of necrosis and
generally were much smaller (Fig. 3). Important changes in
VOL. 77, 2009 IMMUNOTHERAPY FOR PNEUMONIC BURKHOLDERIA INFECTION 1581
spleen pathology were not observed between CLDC-treated
and untreated mice. Thus, these studies demonstrated that
CLDC immunotherapy significantly reduced bacterial replica-
tion and organ pathology in mice infected with B. mallei com-
pared to those for infected mice not receiving immunotherapy.
CLDC-elicited cytokines block B. mallei infection of alveolar
macrophages in vitro. The fact that the i.n. administration of
CLDC elicited a significant decrease in bacterial replication in
the lungs suggested that treatment triggered the release of
cytokines that were capable of eliciting antibacterial activity in
macrophages. For example, it is known that the delivery of
liposome-DNA complexes to the lungs can elicit the local pro-
duction of IFN- and TNF- (6). To investigate this mecha-
nism further and identify possible protective cytokines, we
FIG. 1. Protective effects of CLDC against pneumonic Burkholderia infection are dependent on the timing and dose of CLDC administered.
(A) BALB/c mice (n  5 animals per group) were challenged i.n. with 1  104 CFU B. mallei, and the effects of the timing of the administration
of CLDC immunotherapy on survival were assessed. Mice were untreated or were treated with CLDC 24 h prior to infection, at the time of
infection, or 24 h after infection, and survival times were determined as described in Materials and Methods. (B) The effects of the CLDC dose
on the induction of protective immunity were assessed. Mice (n  5 animals per group) were treated by the i.n. administration of standard CLDC
or CLDC diluted 1:2 or 1:20 24 h before i.n. challenge with 1  104 CFU B. mallei, and survival times were determined. (C) BALB/c mice (n 
5 per group) were untreated or were treated with CLDC 24 h prior to i.n. infection with 10 LD50 (1  10
4 CFU) of B. pseudomallei. Statistical
differences for the data shown were determined by Kaplan-Meier analysis followed by a log-rank test (**, P 0.01). Data shown in all three panels
are representative of two independent experiments each.
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used an in vitro infection system consisting of AMJ2 cells (an
alveolar macrophage line) and supernatants from spleens of
mice that had been injected i.v. with CLDC. In a previous
study, we found that spleen cells were a major source of cyto-
kine production in CLDC-treated mice (11). AMJ2 cells were
treated with CLDC supernatants (or supernatants from un-
treated control mice) for 24 h. The cells then were infected
with B. mallei at an MOI of 2, and 24 h later the numbers of
intracellular bacteria were determined.
The preincubation of macrophages with supernatants from
CLDC-treated mice, but not supernatants from untreated con-
trol mice, resulted in significant reduction in the numbers of
viable intracellular B. mallei (Fig. 4). We also observed the
inhibition of B. mallei infection in macrophage cultures with
supernatants from CLDC-stimulated lungs, but the effect was
much less potent than that with spleen supernatants (data not
shown). Significant antibacterial activity was observed when
supernatants were diluted 1:1 (not shown) or 1:10, but it was
lost when supernatants were diluted 1:100. In previous studies,
CLDC were shown to elicit large amounts of IFN- and
smaller amounts of TNF-, both of which have antibacterial
activity against Burkholderia (4, 29, 30). Therefore, we used
neutralization experiments to assess the relative contribution
of each cytokine to antibacterial activity. The neutralization of
IFN- activity resulted in the significant abrogation of the
macrophage antibacterial activity of CLDC supernatants (Fig.
4). In contrast, the neutralization of TNF- activity had a much
smaller effect. However, the neutralization of both cytokines
resulted in the greater inhibition of antibacterial activity, sug-
gesting that TNF- production contributed to the effectiveness
of IFN- in suppressing B. mallei replication in infected mac-
rophages. Finally, the pretreatment of AMJ2 cells with 10, 1, or
FIG. 2. Effects of CLDC immunotherapy on bacterial burden in
the lung, liver, and spleen of mice following inhalational challenge with
B. mallei. BALB/c mice (n  5 per group) were treated with CLDC by
i.n. administration 24 h prior to challenge and then challenge by the
inhalation of 1  104 CFU B. mallei. Bacterial burdens (in CFU) were
determined in each organ 72 h after B. mallei challenge, as described
in Materials and Methods. Significant reductions in bacterial burdens
were seen in mice treated with CLDC in all three organs analyzed, as
assessed by a two-tailed Student’s t test (***, P  0.001). Data are
representative of two independent experiments.
FIG. 3. Comparison of lung and liver pathology in untreated and CLDC-treated mice following lethal B. mallei challenge. BALB/c mice (n 
5 per group) were untreated or were treated with CLDC 24 h prior to i.n. infection with 104 CFU B. mallei. On day 3 after infection, mice were
euthanized and lung and liver tissues were collected and processed for histopathological evaluation, as described in Materials and Methods.
Representative sections from lung (2 magnification) and liver (20 magnification) from untreated and CLDC-treated mice were photographed.
Images are representative of those obtained in two independent experiments.
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0.1 ng/ml recombinant IFN- resulted in 100, 98, and 98%
inhibition of bacterial growth, respectively (data not shown).
These results indicated that the CLDC-induced production of
IFN- mediated many of the protective effects of CLDC im-
munotherapy noted in vivo, particularly since we have ob-
served that alveolar macrophages are one of the primary early
target cells for Burkholderia infection in the lungs (data not
shown).
i.n. administration of CLDC elicits production of IL-12 and
IFN- in the lungs. Both IL-12 and IFN- are known to play
critical roles in protective immunity to Burkholderia infection
(2, 18–20, 29, 30). In addition, the preceding in vitro studies
indicated that IFN- could control Burkholderia replication in
alveolar macrophages, a likely target cell for the inhalational
route of infection. Therefore, we assessed the ability of the
inhalational delivery of CLDC to elicit IL-12 and IFN- pro-
duction in the lungs. Six and 24 h after the i.n. administration
of CLDC, IL-12 and IFN- concentrations in lung tissues were
determined by ELISA (Fig. 5). Significant increases in the
concentrations of both IL-12 and IFN- were observed in lung
tissues 24 h following the i.n. delivery of CLDC, with smaller
increases noted at 6 h after administration. These results indi-
cated that the inhalational delivery of relatively low doses of
CLDC to the lung could trigger the significant production of a
key cytokine (IFN-) responsible for suppressing the intracel-
lular replication of B. mallei. The kinetics of cytokine induction
in the lung in response to CLDC immunotherapy also may
explain why pretreatment with CLDC 24 h before challenge
did elicit protective immunity, whereas treatment 6 h after
challenge did not.
FIG. 4. IFN- elicited by CLDC treatment inhibits the B. mallei
infection of alveolar macrophages in vitro. (A) AMJ2 (an alveolar
macrophage cell line) cells in triplicate wells of 24-well plates were
treated 24 h prior to infection with supernatants generated from
CLDC-treated or untreated mouse spleen cells, as described in Mate-
rials and Methods. The cells then were infected with B. mallei, and 24 h
later the numbers of intracellular B. mallei organisms were deter-
mined. The treatment of AMJ2 cells with CLDC supernatant resulted
in a significant reduction (P  0.01) in the numbers of intracellular B.
mallei organisms. (B) Neutralizing antibodies to IFN- and TNF-
were utilized to determine the key cytokines present in CLDC-stimu-
lated spleen supernatants that were responsible for the inhibition of B.
mallei infection in macrophages, as described in Materials and Meth-
ods. The neutralization of IFN- resulted in the significant (P  0.05)
inhibition of the antibacterial activity of CLDC supernatants against
the B. mallei infection of AMJ2 cells. In contrast, the inhibition of
TNF- alone did not significantly inhibit CLDC activity. Statistical
significance was assessed using ANOVA, followed by Tukey’s multiple
means comparison test. These results are representative of those ob-
tained in three independent experiments.
FIG. 5. Induction of IL-12p40 and IFN- production in the lungs
following the i.n. administration of CLDC. BALB/c mice (n  5 per
group) were treated with CLDC i.n. and then were euthanized 6 or
24 h after treatment. Concentrations of IL-12p40 and IFN- were
determined in homogenized lung tissues by ELISA, as described in
Materials and Methods. A one-way ANOVA followed by Tukey’s
multiple means comparison test was used to determine significant
differences between the three treatment groups (**, P  0.01; ***,
P  0.001; compared to results for untreated samples). Significant
increases in both IL-12 and IFN- were observed 24 h after the ad-
ministration of CLDC. Data are representative of two independent
experiments.
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IFN- is necessary for CLDC-mediated protection in vivo.
Experiments next were conducted to directly elucidate the in
vivo role of IFN- in CLDC-mediated protection from lethal
challenge with B. mallei. For these experiments, we used IFN-
/ mice on the BALB/c background. In addition, a much
lower challenge dose of B. mallei was administered (0.5 LD50
or 500 CFU), since IFN-/ mice are known to be exquisitely
sensitive to Burkholderia infection (29, 30). Untreated IFN-
/ mice, IFN-/ mice treated with CLDC 24 h prior to
infection (IFN-/ plus CLDC), and wild-type BALB/c mice
were infected with 0.5 LD50 (500 CFU) of B. mallei i.n. (Fig. 6).
We observed that the CLDC pretreatment of IFN-/ mice
failed to elicit protective immunity, indicating that IFN- was
a key component of the protective immunity elicited by CLDC
immunotherapy.
The role of IFN- in suppressing B. mallei replication in vivo
also was assessed. Bacterial burdens in the lung, liver, and
spleen of IFN-/ mice treated with CLDC were compared
to those of untreated IFN-/ mice and wild-type mice on
day 2 after low-dose i.n. challenge with B. mallei. As expected,
the numbers of bacteria in all three organs from IFN-/
mice were significantly higher than those in organs from wild-
type mice (Fig. 6). However, significant differences were not
observed when the numbers of bacteria in untreated IFN-/
mice and CLDC-treated IFN-/ mice were compared (Fig.
6). Thus, these data are consistent with the conclusion that
IFN- was necessary for CLDC immunotherapy to effectively
suppress B. mallei replication and to increase survival following
pulmonary challenge.
Role of NK cells in CLDC-induced protection from B. mallei
challenge. Previous studies have indicated that NK cells were
the major source of IFN- production following systemic (i.v.)
treatment with CLDC (10, 34). However, the role of NK cells
in mediating CLDC-induced pulmonary immunity to bacterial
challenge has not been explored previously. Prior studies have
revealed that multiple cell types, including macrophages,
CD8 T cells, and NK cells, produce IFN- in response to
Burkholderia infection (14, 29). To elucidate the role of NK
cells in CLDC protection, NK cells were depleted systemically
using the asialo GM1 antibody (9, 11, 13, 16). The antibody
was administered 48 h prior to infection, and then the mice
were treated 24 h prior to infection by the i.n. administration of
CLDC. Mice then were infected with 10 LD50 of B. mallei
and monitored for survival.
There was a significant reduction in survival (P  0.01) of
CLDC-treated mice depleted of NK cells compared to that of
CLDC-treated mice not depleted of NK cells (Fig. 7). How-
ever, CLDC-treated and NK-depleted mice still had a signifi-
cant improvement in survival compared to that of untreated
mice (Fig. 7). Thus, these results indicated that NK cells were
necessary for full CLDC-mediated protection. However, par-
tial protection still was observed in NK cell-depleted mice,
suggesting either that other cell types besides NK cells also
contributed to the protective effects of CLDC therapy or that
the residual NK cells not depleted by the administration of
anti-asialo GM1 antibody were sufficient to elicit partial pro-
tection.
The role of NK cells in regulating the bacterial burden also
was assessed. Bacterial burdens in the lung, liver, and spleen of
mice depleted of NK cells and treated with CLDC were de-
termined 3 days after infection. Bacterial burdens in NK cell-
depleted and CLDC-treated mice were significantly increased
in all three organs compared to those of mice treated with
CLDC immunotherapy alone (Fig. 7). In addition, significant
reductions in bacterial burdens also were observed in NK cell-
depleted and CLDC-treated mice compared to those of un-
treated mice. These results are consistent with the idea that
NK cells activated by CLDC immunotherapy contribute to
antibacterial activity, most likely by the secretion of IFN-.
Nitric oxide production is not necessary for CLDC-mediated
protection. The preceding in vitro and in vivo experiments
demonstrated that IFN- was critical to the therapeutic effec-
tiveness of CLDC immunotherapy. IFN- also is known to be
a potent inducer of NOS2 (iNOS) activity, with the subsequent
production of nitric oxide (24). Several in vitro studies utilizing
both B. pseudomallei and B. mallei have demonstrated that the
preactivation of cells with IFN- results in nitric oxide produc-
FIG. 6. IFN- is necessary for the in vivo protective of CLDC
immunotherapy. (A) BALB/c wild-type mice (n  5 per group) or
IFN-/ mice (n 5) were treated with CLDC 24 h prior to infection
or were left untreated. Mice were infected by low-dose challenge using
the i.n. administration of 5  102 CFU B. mallei, and survival was
assessed. Survival times in the IFN-/ mice treated with i.n.-admin-
istered CLDC were not significantly different in terms of infection than
untreated IFN-/ mice. Statistical differences were determined by
Kaplan-Meier analysis using a log-rank test (**, P  0.01 compared to
results for the wild type). Similar results were obtained in a second
experiment done in IFN-/ mice on a C57BL/6 background.
(B) Wild-type BALB/c mice (n  5) or IFN-/ mice (n  5) were
treated with i.n.-administered CLDC 24 h prior to infection or were
left untreated. Mice were infected with 5  102 CFU B. mallei, and on
day 2 after infection mice were euthanized and bacterial burdens in the
lungs, liver, and spleen were determined, as described in Materials and
Methods. The bacterial burdens in all three organs of IFN-/ mice
treated with CLDC were not significantly different from those of un-
treated IFN-/ mice. Similar results were obtained in a second
experiment done in IFN-/ mice on a C57BL/6 background. Statis-
tical analysis was performed using a one-way ANOVA followed by
Tukey’s multiple means comparison test (***, P  0.001 compared to
results for the wild type).
VOL. 77, 2009 IMMUNOTHERAPY FOR PNEUMONIC BURKHOLDERIA INFECTION 1585
tion, which in turn mediates bacterial killing. Other in vitro
studies have shown that Burkholderia species may downmodu-
late nitric oxide production in order to enhance its survival (3,
15, 23, 35, 36). In contrast to the results obtained in these in
vitro studies, in vivo B. pseudomallei challenge studies using
NOS2/ mice have failed to demonstrate a role for nitric
oxide in controlling infection (8).
Given the critical role of IFN- in mediating the protective
effects of CLDC immunotherapy, we wished to determine
whether the induction of iNOS activity and nitric oxide pro-
duction was necessary for CLDC activity. To address this ques-
tion, we used the iNOS inhibitor AG to block the production
of nitric oxide in vivo. Mice were treated with AG beginning 5
days prior to infection. Mice then were treated with CLDC i.n.
24 h prior to infection and then were infected i.n. with 15
LD50 (1.5 10
4 CFU) of B. mallei. We observed that pretreat-
ment with AG had no effect on CLDC protection (Fig. 8). To
ensure that the AG treatment protocol we used effectively
inhibited nitric oxide production, in a separate experiment we
injected AG-treated mice with lipopolysaccharide and assessed
nitric oxide production in serum 6 h later, and we found that
AG treatment completely suppressed lipopolysaccharide-in-
duced nitric oxide production (data not shown). Moreover, in
naive mice not treated with AG, we also noted that CLDC
treatment failed to induce detectable nitric oxide production in
lung tissues or alveolar lavage fluid (data not shown). By real-
time PCR analysis, we also failed to observe increased iNOS
expression in lung tissues of mice treated with CLDC (data not
shown). Thus, several lines of evidence indicated that the in-
duction of nitric oxide production was not critical for CLDC-
mediated protection from pneumonic infection with B. mallei,
although we cannot completely rule out a minor role for NO in
protection.
DISCUSSION
The results presented here indicated that the mucosal deliv-
ery of a potent activator of innate immunity could provide
significant protection from lethal pneumonic infection with
both B. mallei and B. pseudomallei. The most effective protec-
tion was achieved when mice were pretreated with CLDC 24 h
prior to challenge, which suggested that critical immune pro-
tective mechanisms had to be active at the time of initial
contact with the inhaled bacteria to be fully effective. The local,
but not systemic, induction of IFN- release was required for
protection, and protection appeared to be independent of ni-
tric oxide production. Although previous studies found that the
systemic administration of CpG-based immunotherapeutics
could protect mice from the development of chronic pneumo-
nia following low-dose Burkholderia challenge, these are the
first studies to our knowledge to demonstrate effective pro-
tection from acutely lethal respiratory Burkholderia infec-
tion following the inhalational delivery of an immunother-
apeutic (2, 41).
IFN- played a critical role in the protective effects elicited
by CLDC immunotherapy. In support of this, we observed that
IFN-/ mice were completely unprotected by CLDC immu-
notherapy. It is likely that the primary source of IFN- pro-
duction elicited by CLDC was from activated NK cells. The
potent activation of NK cells and IFN- release from the lungs
has been reported previously following CLDC immunotherapy
(11). In the current study, we also demonstrated that NK cells
played a role in the protective effects mediated by CLDC.
However, the requirement for NK cells to mediate the protec-
FIG. 7. Natural killer cells play an important role in the protective
effects of CLDC immunotherapy. (A) BALB/c mice (n  10 per
group) were depleted of NK cells by the i.p. administration of an NK
cell-depleting antibody 48 h prior to infection, as described in Mate-
rials and Methods. Control mice were treated with an irrelevant con-
trol rabbit antibody. Twenty-four hours after NK cell depletion, one
group of mice was treated by the i.n. administration of CLDC immu-
notherapy, and 24 h later the mice were subjected to infection with 104
CFU B. mallei and survival times were assessed. The third group of NK
cell-depleted mice was not treated with CLDC but was subjected to B.
mallei challenge 48 h later. Statistical differences were determined by
Kaplan-Meier analysis using a log-rank test (*, P  0.05). (B) The
effects of NK cell depletion and CLDC treatment on bacterial burdens
in lung, liver, and spleen tissues were assessed 72 h after i.n. infection
with B. mallei. Treatment groups are the same as those noted for panel
A. Statistical analysis was performed using a one-way ANOVA fol-
lowed by Tukey’s multiple means comparison test. (*, P  0.05; **, P
 0.01; and ***, P  0.001).
FIG. 8. Nitric oxide production is not necessary for the protective
effects of CLDC immunotherapy. BALB/c mice (n  5 per group)
were treated i.p. twice daily with AG (or PBS) starting 5 days prior to
infection and continuing until 7 days postinfection, as described in
Materials and Methods. Mice were treated i.n. with CLDC 24 h prior
to infection with 15 LD50 (1.5  10
4 CFU) of B. mallei i.n., and
survival times were determined. Statistical differences were deter-
mined by Kaplan-Meier analysis and a log-rank test. Data are repre-
sentative of two independent experiments.
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tive effects of CLDC was more apparent at lower challenge
doses. For example, NK-depleted, CLDC-treated mice chal-
lenged with 8 LD50 (8  10
3 CFU) had a 60 to 80% survival
rate, whereas mice infected with 12 LD50 (1.2  10
4 CFU)
has only a 20% survival rate. Nevertheless, both of these chal-
lenge doses produced 100% mortality in untreated mice.
Despite a series of in vitro studies that have shown that nitric
oxide is important for the bactericidal effects of IFN- against
both B. pseudomallei and B. mallei, in our studies we failed to
find a role for nitric oxide in CLDC-mediated protective ac-
tivity (3, 15, 23, 35, 36). Our findings thus are in agreement
with a previous in vivo study wherein mice lacking the iNOS
gene (NOS2/) did not exhibit increased susceptibility to B.
pseudomallei infection (8). Thus, we concluded that CLDC-
mediated protection from lethal B. mallei pneumonia was
largely independent of nitric oxide production.
Although the mucosal administration of CLDC elicited
complete protection against acute B. mallei infection, the in-
fection was not completely eliminated. For example, when
mice surviving the acute challenge were monitored out to 60
days, we observed the recrudescence of infection in the spleens
and livers of 80 to 90% of mice. Thus, it would be important to
follow up CLDC immunotherapy with conventional antimicro-
bial therapy to assure the complete eradication of Burkhold-
eria. In summary, these studies indicate that appropriately
timed mucosally administered immunotherapy may induce ef-
fective nonspecific protection against pneumonic intracellular
bacterial pathogens such as B. mallei and B. pseudomallei.
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